Sunnyvale, Calif.-based Accuray Inc. announces that the company has received 510(k) clearance from the U.S. FDA for its ClearRT Helical kVCT Imaging for the Radixact System, the latest TomoTherapy platform. Accuray is planning commercial release of the ClearRT Helical kVCT Imaging for the Radixact System in the spring of 2021.
ClearRT delivers enhanced imaging capabilities compared to conventional linear accelerator systems that rely on cone-beam CT (CBCT) imaging and as an alternative to MR-based radiation therapy systems. ClearRT offers advanced uniformity and low noise across the entire image, improved soft tissue visualization, and high spatial resolution, which is intended to enhance the versatility and efficiency of the Radixact System in the radiation therapy department.
The ClearRT imaging solution is integrated into the Radixact System. Helical fan-beam imaging available at both kV and MV wavelengths provides medical care teams the flexibility to fulfill the patient imaging requirements necessary for accurate patient setup and registration, including imaging patients with metal implants contraindicated for MR imaging.
“ClearRT is a novel, helical CT imaging solution that we believe addresses an unmet market need,” says Suzanne Winter, chief commercial officer and senior vice president, R&D at Accuray. “It integrates with other Accuray-only applications, such as Synchrony Real-time Motion Synchronization and Adaptive Treatment Delivery Technology, on the Radixact System, making it possible for providers to offer a new level of precision and accuracy in the treatment of the simplest to the most complex pathologies.”
Winter adds: “Our continuing innovation on the Radixact System is designed to leverage the power of its 360-degree, helical delivery platform to facilitate advanced, hypofractionated, and ultra-hypofractionated treatments that support our customers’ efforts to maintain the highest standard of care for their community.”
